Global Health News - Week ending 4 October 2026

MSF staff member with Bundibugyo virus disease medically evacuated from DR Congo to the Netherlands

Medecins Sans Frontieres (MSF) reported that one of its staff members working on the Ebola response in the Democratic Republic of the Congo (DRC) had tested positive for Bundibugyo virus disease and was medically evacuated under a strict medical protocol, coordinated with the health authorities of the DRC and the Netherlands, to a designated hospital in the Netherlands. MSF gave no further personal details, citing confidentiality. The organisation described the outbreak as the largest Ebola disease outbreak ever recorded in the DRC, with more than 8,000 confirmed cases and more than 4,000 deaths since May 2026, and warned that the true toll was likely higher because of gaps in surveillance and case detection. MSF said its teams were responding across Ituri, North Kivu, Tshopo and Haut-Uele provinces, where the outbreak continued to strain health services and response capacity.

Why it matters: Bundibugyo virus disease has no approved vaccine or specific treatment, so this case shows pharmacy and healthcare students how outbreak response relies on strict infection prevention, rapid evacuation protocols and cross-border coordination between health authorities.

Source: Medecins Sans Frontieres, 1 October 2026

World Top Stories

Phase 3 TRIUMPH-1 trial of retatrutide published in the New England Journal of Medicine

The full results of TRIUMPH-1, a phase 3 randomised, double-blind, placebo-controlled trial of the investigational triple-receptor agonist retatrutide, were published online on 29 September 2026. The trial assigned 2,339 adults with obesity but without diabetes to once-weekly injections of retatrutide at three dose levels or placebo for 80 weeks. Average body weight fell by 17.6 percent, 23.7 percent and 25.0 percent across the three retatrutide dose groups, compared with 3.9 percent in the placebo group, with the differences for the two higher doses statistically significant. Participants with knee osteoarthritis reported reduced pain scores and participants with obstructive sleep apnoea had fewer breathing interruption events, while the most common adverse events were gastrointestinal. The trial was funded by Eli Lilly, and retatrutide remained investigational and unapproved at the time of publication.

Why it matters: This is a landmark obesity trial for students to study, because it tests a single molecule acting on three hormone receptors at once and reports outcomes beyond weight, including joint pain and sleep apnoea, alongside a clear safety profile.

Source: New England Journal of Medicine, 29 September 2026

Phase 3 TRIUMPH-2 trial of retatrutide in type 2 diabetes published in The Lancet

The Lancet published the TRIUMPH-2 trial online on 29 September 2026, reporting results in 1,152 adults with obesity and type 2 diabetes recruited at 92 centres across eight countries. Participants were randomised to once-weekly retatrutide at three dose levels or placebo for 80 weeks, on top of stable diabetes treatment, and average body weight fell by 11.9 percent, 16.8 percent and 18.8 percent across the retatrutide groups, compared with 5.1 percent on placebo. The authors also reported improved blood sugar control in the retatrutide groups, with a safety profile they described as generally consistent with other medicines acting on the GLP-1 receptor. Gastrointestinal events were the most frequent adverse events, diarrhoea affected 27 to 34 percent of retatrutide participants against 13 percent on placebo, and treatment discontinuation because of adverse events or death was higher in the two higher dose groups. All deaths recorded during the trial were judged by investigators to be unrelated to the study intervention, and the trial was funded by Eli Lilly.

Why it matters: TRIUMPH-2 matters for students because weight loss is typically smaller in people with type 2 diabetes, so a trial showing substantial weight loss plus improved glycaemic control in this population changes how future diabetes and obesity pharmacotherapy is discussed.

Source: The Lancet, 29 September 2026

WHO and the Netherlands strengthen partnership on global health security and emergency response

The World Health Organization (WHO) and the Netherlands reaffirmed their partnership on global health security at a senior leadership meeting on 30 September 2026, with the announcement published on 1 October 2026. WHO Director-General Dr Tedros Adhanom Ghebreyesus thanked Mr Sjoerd Sjoerdsma, Minister for Foreign Trade and Development Cooperation, for Dutch leadership on health security, emergency preparedness and response, resilient health systems, and sexual and reproductive health and rights. The partnership reflects the Netherlands Global Health Strategy 2023 to 2030, and Dr Tedros welcomed continued flexible and predictable financing for WHO. Dutch support contributes to WHO work in Gaza, Ukraine and the DRC, covering essential health services, disease surveillance, outbreak control and medical supplies, and the two sides also discussed the Ebola outbreak, access to essential health services for Palestinian patients from Gaza, attacks on health care, and WHO transformation.

Why it matters: For students, this shows how a single country's flexible funding underpins outbreak surveillance, emergency supplies and essential services in several crises at once, and why predictable financing is a recurring theme in global health policy.

Source: World Health Organization, 1 October 2026

Health ministers approve new regional strategy against dengue and other arboviral diseases in the Americas

Member states of the Pan American Health Organization (PAHO) approved a common regional framework at the organisation's 63rd Directing Council on 1 October 2026, to strengthen surveillance, prevention, preparedness and integrated response to dengue and other arboviral diseases over the next decade. The decision follows a period of larger outbreaks, simultaneous circulation of several arboviruses and geographic expansion of the mosquitoes that transmit them, with the Region of the Americas recording more than 13 million dengue cases and over 8,400 deaths in 2024, its largest epidemic on record. The strategy sets four priority areas: integrated arboviral disease management; epidemiological, entomological and virological surveillance; health system capacity for early detection, diagnosis and clinical management; and modernised integrated vector management, including Wolbachia-infected and irradiated mosquitoes. It aims to move the region from reactive responses to anticipatory, risk-based approaches using combined epidemiological, entomological, virological and laboratory data for early warning, under a One Health approach, with technical implementation guided by the Integrated Management Strategy for the Prevention and Control of Arboviral Diseases 2026 to 2035 and progress reports scheduled for 2031 and 2036.

Why it matters: Dengue and related arboviruses are core topics for pharmacy and public health students, and this strategy links vector control, laboratory surveillance and clinical management into a single regional plan rather than treating outbreaks one by one.

Source: Pan American Health Organization, 1 October 2026

WHO and partners showcase first Pandemic Fund multi-country project in the Western Pacific

WHO, the Asian Development Bank, the Asian Infrastructure Investment Bank, the Food and Agriculture Organization and the Pandemic Fund Secretariat introduced Data to Action, the Pandemic Fund's first multi-country project in the Western Pacific Region, on 1 October 2026. The project brings together 12 countries and areas (Kiribati, Lao People's Democratic Republic, Malaysia, Marshall Islands, the Federated States of Micronesia, Nauru, Palau, Papua New Guinea, the Philippines, Tonga, Tuvalu and Viet Nam) to close persistent gaps in surveillance, laboratory capacity and emergency workforce readiness, using a country-led, multisectoral design built around the One Health approach. It will strengthen multisource surveillance systems, expand laboratory networks and diagnostic capacity, and build a skilled One Health workforce so that an outbreak detected in one country can trigger a coordinated regional response before it spreads. The project is backed by a grant of 35.99 million US dollars from the Pandemic Fund, which has catalysed more than 151 million US dollars in additional co-financing and more than 37 million US dollars in co-investment from participating governments.

Why it matters: Students can see here how pandemic preparedness is financed in practice, with a relatively modest seed grant unlocking much larger co-financing, and how laboratory networks and specimen referral systems are shared across small island states.

Source: World Health Organization, 1 October 2026

Global regulators call for advancing alternatives to animal testing for human medicines

The UK Medicines and Healthcare products Regulatory Agency (MHRA) joined international medicines regulators on 1 October 2026 in a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling for alternatives to animal testing to be advanced and implemented throughout the lifecycle of human medicines, wherever and as soon as possible. The statement, developed by the European Medicines Agency, the MHRA, the Irish Health Products Regulatory Authority and Swissmedic and adopted by the ICMRA plenary, sets the long-term goal of replacing animal testing at every stage, from initial screening and early development through non-clinical testing, licensing and post-authorisation activities. It calls on developers to use non-animal methods that are acceptable in a regulatory context while safeguarding scientific quality, and on regulators to support those efforts as far as possible. Recognising that batch release testing offers the greatest scope for reducing animal use, ICMRA calls on regulators to encourage non-animal batch release tests, challenge proposals to use animals, approve animal testing for batch release only where scientifically justified, and review existing animal testing requirements for batch release.

Why it matters: This is directly relevant to pharmacy students studying drug development and regulation, because it signals how evidence standards for new medicines may shift towards validated non-animal methods such as organ-on-a-chip systems and computational models.

Source: Medicines and Healthcare products Regulatory Agency, 1 October 2026

One Health unites Pacific countries against health, environmental and climate threats as El Nino bites

Pacific countries and areas adopted an integrated One Health approach spanning human, animal, plant and environmental health at the second Pacific One Health Workshop in Fiji, reported on 2 October 2026. The workshop reviewed progress since the first workshop in 2024 and brought together government representatives and regional and international partners to discuss zoonotic and vector-borne diseases including dengue, chikungunya and leptospirosis, which remain widespread in several Pacific island countries, driven by environmental change, habitat disruption and shifting weather patterns. Delegates heard that drought and rising temperatures linked to an ongoing El Nino were increasing the risk of diarrhoeal diseases and malnutrition, and highlighted a joint plan of action for coordination at national, regional and global levels. Topics covered included One Health governance, surveillance, risk assessment, pandemic preparedness, food safety, antimicrobial resistance, environmental integration and climate-related health risks, with the workshop jointly organised by the Food and Agriculture Organization, the United Nations Environment Programme, WHO and the World Organisation for Animal Health, alongside the Pacific Community and the Secretariat of the Pacific Regional Environment Programme.

Why it matters: One Health is a recurring examination and practice theme, and this workshop shows students how climate events such as El Nino translate into concrete disease risks, from vector-borne infection to malnutrition, in island health systems.

Source: World Health Organization, 2 October 2026

WHO Yemen conflict escalation situation report records rising casualties, displacement and cholera

WHO's Regional Office for the Eastern Mediterranean issued Yemen Conflict Escalation Situation Report number 6 on 4 October 2026, covering 27 September to 2 October 2026. The report recorded 685 new casualties in six days, an average of 114 per day against 101 in the previous period, taking the cumulative total since 6 August to 5,166 casualties with 959 deaths, a case fatality ratio of 18.6 percent. Taiz became the heaviest front, with daily casualties rising from 8 to 109 within the week as fighting moved into Taiz city, while conflict spread to Hadramout and Al-Jawf for the first time and Lahj and Marib remained severe. Almost 200,000 people were displaced, with 29,519 families across ten governorates, while cholera tripled in three weeks (647 suspected cases in week 39 against 217 in week 36) and measles continued to spread through an immunity gap, with more than 22,000 suspected cases and 128 deaths reported in 2026 to week 38. The report also flagged that six of 20 planned Tier 1 Trauma Stabilization Points had no partner support, about half of health facilities in affected governorates had no partner support, and the Scenario 2 response was costed at 9 million US dollars with only 2 million secured, leaving a gap of 7 million.

Why it matters: This report is a compact case study for students in conflict and humanitarian health, linking trauma care gaps, displacement, cholera and measles resurgence, and the funding shortfalls that shape what frontline services can actually deliver.

Source: World Health Organization Regional Office for the Eastern Mediterranean, 4 October 2026

South Asia

Only 2 stories met the bar this week

Bangladesh charts renewed path towards zero leprosy following Joint Monitoring Mission

The Government of Bangladesh committed to accelerated action towards a leprosy-free country following the conclusion of the 2026 Joint Monitoring Mission on Leprosy, held from 21 to 28 September, as reported by WHO on 30 September 2026. The government-led mission brought together national and international experts to assess the National Leprosy Programme, visiting health facilities and communities across areas with different levels of leprosy burden, and to identify actions needed to interrupt transmission in line with the WHO Global Leprosy Strategy vision of zero disease, zero disability and zero discrimination. Bangladesh achieved elimination of leprosy as a public health problem in 1998, but transmission continues, with 3,558 new cases reported in 2025, including 185 among children, and 208 people diagnosed with Grade 2 disability. Immediate priorities for the coming year include reaffirming political commitment and sustainable financing around an updated national strategy for leprosy-free upazilas, strengthening surveillance through case-based reporting, expanding case investigation and contact tracing, and increasing community engagement, while medium-term actions through 2030 include nationwide preventive treatment for eligible contacts, stronger diagnostic and referral services, and greater involvement of people affected by leprosy in planning and care.

Why it matters: Leprosy remains a neglected tropical disease teaching topic, and this story shows students why elimination as a public health problem is not the same as interrupting transmission, especially when children are still being diagnosed.

Source: World Health Organization, 30 September 2026

With WHO and partner support, Bangladesh launches independent review of its immunisation programme

The Government of Bangladesh launched an independent review of its Expanded Programme on Immunization and vaccine-preventable disease surveillance on 4 October 2026, with WHO and national and international partner support, running from 4 to 14 October with teams at national level and across all eight divisions. Initiated at the Government's request, the review aims to assess performance comprehensively, identifying strengths, gaps and priority actions so that every person is reached with life-saving vaccines. Bangladesh's immunisation programme has delivered major gains since its establishment in 1979, including remaining polio-free for more than 15 years, sustained elimination of maternal and neonatal tetanus, and control of rubella, but the 2026 measles outbreak highlighted persistent immunity gaps and vulnerabilities. The review examines seven areas (programme management and financing; human resources; vaccine supply, cold chain, quality and logistics; service delivery; immunisation coverage, safety monitoring and data; disease surveillance, outbreak preparedness and response; and communication and demand generation), using data analysis, consultations and direct observation of health facilities, vaccination sessions, cold-chain and data systems, with field sites covering higher- and lower-performing areas, urban communities and hard-to-reach populations. International participants include WHO headquarters and the WHO South-East Asia Regional Office, UNICEF, the International Federation of Red Cross and Red Crescent Societies, the National Centre for Immunisation Research and Surveillance in Australia, and the Measles and Rubella Initiative, with key findings due on 14 October and a draft report and action plan expected in November.

Why it matters: Independent programme reviews are a core public health skill, and this example shows students how a country audits its own immunisation system after an outbreak exposes immunity gaps, rather than waiting for an external evaluation.

Source: World Health Organization, 4 October 2026

Europe

Only 3 stories met the bar this week

Netherlands reports 12 new West Nile fever patients in a week, with 4 deaths

The Netherlands National Institute for Public Health and the Environment (RIVM) reported on 1 October 2026 that 12 new West Nile fever patients had been recorded since its previous update of 24 September, 4 of whom died, all after being bitten by an infected mosquito. Total reported cases in the Netherlands reached 56, with 9 deaths in 2026, most patients diagnosed after hospital admission with symptoms, and cases spread across South Holland (32), Utrecht (12), North Holland (5), North Brabant (4), Gelderland (2) and Overijssel (1). RIVM said it expected the peak had passed because new infections had decreased in recent weeks. In animals, 14 newly positive horses took the 2026 total to 150, and 7 newly positive birds took the total to 178, while no new positive mosquito pools were found in the last week, leaving the total at 4.

Why it matters: West Nile virus is a textbook One Health example for students, linking mosquito surveillance, bird and horse monitoring, and human case detection in a single national picture.

Source: Netherlands National Institute for Public Health and the Environment, 1 October 2026

ECDC publishes communicable disease threats report for week 40

The European Centre for Disease Prevention and Control (ECDC) published its Communicable Disease Threats Report covering 26 September to 2 October 2026, its weekly bulletin for epidemiologists and health professionals on active public health threats. This issue includes updates on Crimean-Congo haemorrhagic fever, chikungunya virus disease, cholera, COVID-19, dengue, Ebola, avian influenza, seasonal influenza, Middle East Respiratory Syndrome, respiratory syncytial infection, vibriosis and West Nile virus infection. The report is published as an English PDF of 8.98 MB, accompanied by maps and graphs for week 40, giving readers a single consolidated view of the threats under monitoring across Europe and globally at that point in the season.

Why it matters: The weekly threats report is one of the most useful routine sources for students learning outbreak surveillance, because it shows how many different threats are tracked simultaneously and how risk assessment is summarised for professionals.

Source: European Centre for Disease Prevention and Control, 2 October 2026

National Patient Safety Alert issued over discontinuation of Levemir insulin products

A safety-critical National Patient Safety Alert on Levemir (insulin detemir) FlexPen and Penfill products was circulated in Northern Ireland on 2 October 2026, forwarding the UK alert issued on 1 October 2026. The alert states that Levemir products are being discontinued from the end of December 2026, with stocks anticipated to be exhausted by that date, and requires clinicians and prescribers not to initiate any patient on a Levemir product with immediate effect. Community pharmacists presented with prescriptions for Levemir products are asked, after ensuring the patient has sufficient insulin, to refer patients back to their prescriber, highlighting the need to switch to an alternative insulin because of the imminent discontinuation. All existing Levemir patients are to be switched to an alternative insulin in line with locally agreed plans and clinical guidance as soon as possible and no later than 30 November 2026, with teams asked to check the supply position for alternative insulins and diversify prescribing across available alternatives to avoid creating a supply disruption in those products.

Why it matters: Discontinuation alerts are a core pharmacy practice topic, because they test medicines supply management, patient counselling on new devices, and the coordination between prescribers, community pharmacists and specialist diabetes teams.

Source: Northern Ireland Department of Health, 2 October 2026

North America

Only 1 story met the bar this week

FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma

The US Food and Drug Administration (FDA) approved pirtobrutinib on 2 October 2026 for adult patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma with no known 17p deletion, with the product marketed as Jaypirca by Eli Lilly and Company. Efficacy was assessed in BRUIN CLL-313, a randomised, open-label, active-controlled trial in 282 patients without deletion of chromosome 17p, randomised equally to pirtobrutinib until progression or to bendamustine plus a rituximab product for six cycles. The main outcome was progression-free survival assessed by an independent review committee, and at a median follow-up of 28 months, median progression-free survival was not estimable in the pirtobrutinib arm against 33.5 months in the control arm, with a hazard ratio of 0.20 and a p-value below 0.0001. Overall survival data were immature, with median survival not reached in either arm and 13 deaths in total, and the most common non-laboratory adverse reactions at or above 20 percent were upper respiratory tract infections (27 percent), rash (22 percent) and COVID-19 (21 percent), with serious adverse reactions in 28 percent of patients. Warnings in the approval cover infections, haemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity and embryo-foetal toxicity, and pirtobrutinib received orphan drug designation.

Why it matters: This approval is a useful study case for students in oncology pharmacy, showing how a targeted therapy can move into first-line use on progression-free survival data while overall survival data are still immature.

Source: US Food and Drug Administration, 2 October 2026

Africa

Only 1 story met the bar this week

Sierra Leone prioritises its vaccine portfolio under national immunisation advisory leadership

Sierra Leone's National Immunization Technical Advisory Group, working with the Expanded Programme on Immunization and partners including WHO, UNICEF, the Sierra Leone Red Cross Society, CHAI and AFENET, conducted a three-day Vaccine Portfolio Optimization and Prioritization exercise from 28 to 30 September 2026, reported by WHO on 29 September 2026. The exercise marked an important milestone in the country's efforts to strengthen and sustain its immunisation programme and to prepare its application under the Gavi 6.0 strategy, bringing together national stakeholders and development partners to decide which existing vaccines should be optimised over the next five years and to identify priority new vaccine introductions between 2026 and 2030. During the meeting, participants consolidated evidence on optimisation opportunities, developed and assessed prioritisation and sequencing scenarios, drafted and validated recommendations, and prepared a final report for submission to Gavi, with outcomes expected to inform investment decisions shaping the country's immunisation programme for years to come. Sierra Leone reviewed and prioritised opportunities to optimise five vaccines, including measles and rubella, malaria, rotavirus and pneumococcal conjugate vaccines, alongside other antigens identified through the methodology, and also prioritised potential new vaccine introductions addressing emerging public health needs, building on a preparatory workshop held on 3 and 4 September 2026 and aligning with the National Immunization Strategy 2026 to 2030.

Why it matters: This shows students how immunisation policy is actually made in a resource-limited setting, with an advisory group weighing evidence, sequencing and cost to decide which vaccines get priority in a national funding application.

Source: World Health Organization Regional Office for Africa, 29 September 2026

← Newer: Week ending 11 October 2026  ·  All Global Health News

Every story on this page was verified on its original source page. Coverage is pharma, medical, healthcare and community health only; no politics or finance.